Literature DB >> 27721972

Significant weight loss following clozapine use, how is it possible? A case report and review of published cases and literature relevant to the subject.

Tongeji E Tungaraza1.   

Abstract

It has been repeatedly shown that clozapine is more efficacious than other antipsychotics in the management of treatment-resistant schizophrenia. However, clozapine is associated with a number of side effects including weight gain. Antipsychotic-induced weight gain has been linked with a number of untoward events including psychological factors such as stigma and low self-esteem, and physical factors such as metabolic syndromes and untimely death. The mechanism underlying antipsychotic (including clozapine)-induced weight gain is not clearly understood, although it is said to involve several brain areas, several neurotransmitters, neuropeptides and genetic factors. To some individuals however, clozapine use is associated with significant weight loss (13.5-50% of body weight). The observed weight loss in these groups of patients has not been attributed to any underlying diagnosable physical disorders. There have been a handful cases published with this phenomenon, which seems to be contrary to what is expected when clozapine is prescribed. From the currently published cases three groups emerge - those who lost weight simply by taking clozapine, those who lost weight due to improved mental state, engaging in diet and increased exercise, and those for whom weight loss was a sign of a poor response to clozapine. A case of JX who has a diagnosis of schizoaffective disorder is presented. JX lost over 26% of her body weight when she was prescribed clozapine. A detailed review of other published cases is undertaken. The underlying mechanisms involving weight loss are discussed and the implications to clinicians are highlighted. Coordinated studies to examine these groups of patients may provide some insight, not only in the mechanism of clozapine-induced weight loss, but also in the better management of patients with treatment-resistant schizophrenia involving clozapine use.

Entities:  

Keywords:  clozapine; treatment-resistant schizophrenia; weight loss

Year:  2016        PMID: 27721972      PMCID: PMC5036136          DOI: 10.1177/2045125316649534

Source DB:  PubMed          Journal:  Ther Adv Psychopharmacol        ISSN: 2045-1253


  39 in total

1.  Conceptualization and treatment of negative symptoms in schizophrenia.

Authors:  Sonali Sarkar; Kiley Hillner; Dawn I Velligan
Journal:  World J Psychiatry       Date:  2015-12-22

2.  Duration of a clozapine trial in neuroleptic-resistant schizophrenia.

Authors:  H Y Meltzer
Journal:  Arch Gen Psychiatry       Date:  1989-07

Review 3.  Weight gain associated with neuroleptic medication: a review.

Authors:  J M Stanton
Journal:  Schizophr Bull       Date:  1995       Impact factor: 9.306

4.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

5.  Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials.

Authors:  K Wahlbeck; M Cheine; A Essali; C Adams
Journal:  Am J Psychiatry       Date:  1999-07       Impact factor: 18.112

6.  The association between weight change and symptom reduction in the CATIE schizophrenia trial.

Authors:  Eric Hermes; Henry Nasrallah; Vicki Davis; Jonathan Meyer; Joseph McEvoy; Donald Goff; Sonia Davis; T Scott Stroup; Marvin Swartz; Jeffrey Lieberman; Robert Rosenheck
Journal:  Schizophr Res       Date:  2011-02-21       Impact factor: 4.939

7.  Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment.

Authors:  Ric M Procyshyn; Kishor M Wasan; Allen E Thornton; Alasdair M Barr; Eric Y H Chen; Edith Pomarol-Clotet; Emmanuel Stip; Richard Williams; G William Macewan; C Laird Birmingham; William G Honer
Journal:  J Psychiatry Neurosci       Date:  2007-09       Impact factor: 6.186

Review 8.  Endocannabinoid system and cardio-metabolic risk.

Authors:  K Y Loh; S T Kew
Journal:  Med J Malaysia       Date:  2008-10

9.  Clozapine-associated weight loss.

Authors:  R Hanwella; V de Silva; C Wijeratne; T Ketharanathan; J de Silva
Journal:  J Psychopharmacol       Date:  2009-03-05       Impact factor: 4.153

10.  Role of 5-HT(2C) receptor gene variants in antipsychotic-induced weight gain.

Authors:  Tessa Jm Wallace; Clement C Zai; Eva J Brandl; Daniel J Müller
Journal:  Pharmgenomics Pers Med       Date:  2011-08-18
View more
  3 in total

1.  Clozapine-induced Weight Loss and Stuttering in a Patient with Schizophrenia.

Authors:  Soumitra Das; N Manjunatha; Jagadisha Thirthali
Journal:  Indian J Psychol Med       Date:  2018 Jul-Aug

2.  Empagliflozin Effectively Attenuates Olanzapine-Induced Body Weight Gain in Female Wistar Rats.

Authors:  Ghulam Md Ashraf; Badrah S Alghamdi; Fahad S Alshehri; Mohammad Zubair Alam; Haythum O Tayeb; Frank I Tarazi
Journal:  Front Pharmacol       Date:  2021-04-19       Impact factor: 5.810

Review 3.  Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects.

Authors:  Spyridon Siafis; Dimitrios Tzachanis; Myrto Samara; Georgios Papazisis
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.